Abstract
In this study, we sought to determine the accuracy with which the International Classification of Diseases, 9th Edition, Clinical Modification (ICD-9-CM) diagnosis code for “secondary neoplasm of brain and spinal cord” in health insurance claims measures clinically evident central nervous system (CNS) metastases in patients with non-small cell lung cancer (NSCLC). For 241 consecutive patients with newly diagnosed NSCLC, we compared ICD-9-CM “secondary neoplasm” codes indicating tumor spread to the CNS from institutional billing records to gold-standard chart review to determine: (1) sensitivity, specificity and positive predictive value (PPV) of the site-specific secondary neoplasm code and (2) the accuracy in time of its appearance within billing records compared with the gold standard date of CNS relapse. The occurrence of at least one ICD-9-CM code for brain metastasis (Algorithm 1) had a sensitivity of 100% (95% CI: 100–100%) and PPV of 91% (95% CI: 87–94%). By requiring ≥ 2 codes (Algorithm 2) or ≥ 3 codes (Algorithm 3) for the diagnosis of brain metastasis in claims, specificity and PPV improved, while sensitivity did not drop substantially. The claims-based date of diagnosis was also accurate, with 92% of dates falling within 30 days of the gold standard. ICD-9-CM codes in institutional billing claims reliably documented NSCLC metastases to the CNS. These results suggest that Medicare claims data may be used to evaluate clinical and epidemiological issues related to brain metastases in elderly cancer patients.
Similar content being viewed by others
References
Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22:2865–2872. doi:10.1200/JCO.2004.12.149
Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neurooncol 75:5–14. doi:10.1007/s11060-004-8093-6
Schouten LJ, Rutten J, Huveneers HA, Twijnstra A (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94:2698–2705. doi:10.1002/cncr.10541
Johnson JD, Young B (1996) Demographics of brain metastasis. Neurosurg Clin N Am 7:337–344
Percy AK, Elveback LR, Okazaki H, Kurland LT (1972) Neoplasms of the central nervous system. Epidemiologic considerations. Neurology 22:40–48
Posner JB (1996) Brain metastases: 1995. A brief review. J Neurooncol 27:287–293. doi:10.1007/BF00165486
Walker AE, Robins M, Weinfeld FD (1985) Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology 35:219–226
Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061–2067. doi:10.1056/NEJM199912303412706
Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291:2720–2726. doi:10.1001/jama.291.22.2720
Trimble EL, Carter CL, Cain D, Freidlin B, Ungerleider RS, Friedman MA (1994) Representation of older patients in cancer treatment trials. Cancer 74:2208–2214. doi: 10.1002/1097-0142(19941001)74:7+<2208::AID-CNCR2820741737>3.0.CO;2-#
Cooper GS, Yuan Z, Stange KC, Dennis LK, Amini SB, Rimm AA (2000) Agreement of medicare claims and tumor registry data for assessment of cancer-related treatment. Med Care 38:411–421. doi:10.1097/00005650-200004000-00008
Du X, Freeman JL, Goodwin JS (1999) Information on radiation treatment in patients with breast cancer: the advantages of the linked medicare and SEER data. Surveillance, epidemiology and end results. J Clin Epidemiol 52:463–470. doi:10.1016/S0895-4356(99)00011-6
Earle CC, Nattinger AB, Potosky AL, Lang K, Mallick R, Berger M, Warren JL (2002) Identifying cancer relapse using SEER-medicare data. Med Care 40:IV-75–IV-81. doi:10.1097/00005650-200208001-00011
Lamont EB, Herndon JEII, Weeks JC, Henderson IC, Earle CC, Schilsky RL, Christakis NA (2006) Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst 98:1335–1338
Lamont EB, Herndon JEII, Weeks JC, Henderson IC, Lilenbaum R, Schilsky RL, Christakis NA (2005) Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst 97:1080–1083
Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J (2002) Studying radiation therapy using SEER-Medicare-linked data. Med Care 40:IV-49–IV-54
Cooper GS, Yuan Z, Stange KC, Amini SB, Dennis LK, Rimm AA (1999) The utility of Medicare claims data for measuring cancer stage. Med Care 37:706–711. doi:10.1097/00005650-199907000-00010
Du X, Freeman JL, Warren JL, Nattinger AB, Zhang D, Goodwin JS (2000) Accuracy and completeness of Medicare claims data for surgical treatment of breast cancer. Med Care 38:719–727. doi:10.1097/00005650-200007000-00004
Fisher ES, Whaley FS, Krushat WM, Malenka DJ, Fleming C, Baron JA, Hsia DC (1992) The accuracy of Medicare’s hospital claims data: progress has been made, but problems remain. Am J Public Health 82:243–248. doi:10.2105/AJPH.82.2.243
Warren JL, Feuer E, Potosky AL, Riley GF, Lynch CF (1999) Use of Medicare hospital and physician data to assess breast cancer incidence. Med Care 37:445–456. doi:10.1097/00005650-199905000-00004
Acknowledgments
The authors would like to thank Carol Venuti in the Massachusetts General Hospital Cancer Data Registry and Carol Bohondoney in the Patient Billing Department at MGH for their assistance with this project.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Eichler, A.F., Lamont, E.B. Utility of administrative claims data for the study of brain metastases: a validation study. J Neurooncol 95, 427–431 (2009). https://doi.org/10.1007/s11060-009-9943-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-009-9943-z